Page 69 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

110. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus
pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401-
404.
111. Clowse MEB, Eudy AM, Balevic S, et al. Hydroxychloroquine in the pregnancies
of women with lupus: a meta-analysis of individual participant data. Lupus Sci
Med. 2022;9(1):e000651.
112. Do SC, Rizk NM, Druzin ML, et al. Does Hydroxychloroquine Protect against
Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus
Pregnancies? Am J Perinatol. 2020;37(9):873-880.
113. Seo MR, Chae J, Kim YM, et al. Hydroxychloroquine treatment during
pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus.
2019;28(6):722-730.
114. Thaha M, Alsagaff MY, Dwi Suryantoro S, et al. High-dose vs low-dose steroid
in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A
systematic review and meta-analysis. F1000Research. 2022;11:1-16.
115. Tani C, Zucchi D, Haase I, et al. Impact of low-dose acetylsalicylic acid on
pregnancy outcome in systemic lupus erythematosus: results from a multicentre
study. Lupus Sci Med. 2022;9(1):e000714.
116. Klein-Gittelman M, Lane JC, Lane J. Systemic Lupus Erythematosus. In: Petty
R, Laxer R, Lindsley C, Wedderburn L, Cassidy J, editors. Textbook of pediatric
rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2016.
117. Foster HE, Minden K, Clemente D, et al. EULAR/PReS standards and
recommendations for the transitional care of young people with juvenile-onset
rheumatic diseases. Ann Rheum Dis. 2017;76(4):639-646.
118. Felsenstein S, Reiff AO, Ramanathan A. Transition of Care and Health-Related
Outcomes in Pediatric-Onset Systemic Lupus Erythematosus. Arthritis Care Res
(Hoboken). 2015;67(11):1521-1528.
119. Son MB, Sergeyenko Y, Guan H, et al. Disease activity and transition
outcomes in a childhood-onset systemic lupus erythematosus cohort. Lupus.
2016;25(13):1431-1439.
120. Clemente D, Leon L, Foster H, et al. Systematic review and critical appraisal
of transitional care programmes in rheumatology. Semin Arthritis Rheum.
2016;46(3):372-379.
121. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations
for vaccination in adult patients with autoimmune inflammatory rheumatic
diseases. Ann Rheum Dis. 2020;79(1):39-52.
122. Adawi M, Bragazzi NL, McGonagle D, et al. Immunogenicity, safety and
tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus
patients: An evidence-informed and PRISMA compliant systematic review and
meta-analysis. Autoimmun Rev. 2019;18(1):73-92.
123. Liao Z, Tang H, Xu X, et al. Immunogenicity and Safety of Influenza Vaccination
in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A
Meta-Analysis. PLoS One. 2016;11(2):e0147856.
124. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in
immune mediated inflammatory diseases: Systematic review and meta-analysis.
Autoimmun Rev. 2022;21(1):102927.
125. Larsen ES, Nilsson AC, Möller S, et al. Immunogenicity and risk of disease
flare after a three-dose regimen with SARS-CoV-2 vaccination in patients
with systemic lupus erythematosus: results from the prospective cohort study
COVAC-SLE. Clin Exp Rheumatol. 2023;41(3):676-684.
126. Mok CC, Ho LY, To CH. Long-term immunogenicity of a quadrivalent
human papillomavirus vaccine in systemic lupus erythematosus. Vaccine.
2018;36(23):3301-3307.

52